TW203049B
(en)
*
|
1990-04-13 |
1993-04-01 |
Yamanouchi Pharma Co Ltd |
|
DE4123341A1
(en)
*
|
1991-07-15 |
1993-01-21 |
Thomae Gmbh Dr K |
PHENYL ALKYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
|
DK40192D0
(en)
*
|
1992-03-26 |
1992-03-26 |
Neurosearch As |
IMIDAZOLE COMPOUNDS, THEIR PREPARATION AND USE
|
PH31122A
(en)
*
|
1993-03-31 |
1998-02-23 |
Eisai Co Ltd |
Nitrogen-containing fused-heterocycle compounds.
|
CA2131134A1
(en)
*
|
1993-09-17 |
1995-03-18 |
Gerhard Stucky |
Process for preparing imidazopyridine derivatives
|
CA2131680C
(en)
*
|
1993-09-17 |
2006-11-07 |
Gerhard Stucky |
Process for preparing imidazopyridine derivatives
|
MX9700041A
(en)
*
|
1994-06-29 |
1997-04-30 |
Smithkline Beecham Corp |
Vitronectin receptor antagonists.
|
US6228871B1
(en)
|
1995-07-10 |
2001-05-08 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
DE19541146A1
(en)
*
|
1995-10-25 |
1997-04-30 |
Schering Ag |
Imidazole derivatives and their use as nitric oxide synthase inhibitors
|
WO1998006703A1
(en)
|
1996-08-14 |
1998-02-19 |
Warner-Lambert Company |
2-phenyl benzimidazole derivatives as mcp-1 antagonists
|
JP2002510293A
(en)
*
|
1997-05-30 |
2002-04-02 |
ドクター・レディーズ・リサーチ・ファウンデーション |
Novel benzimidazole derivatives as anti-ulcer agents, methods for their preparation, and pharmaceutical compositions containing them
|
IL133800A0
(en)
|
1997-07-03 |
2001-04-30 |
Du Pont Pharm Co |
Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
|
EP1012151B1
(en)
|
1997-09-02 |
2002-08-07 |
Bristol-Myers Squibb Pharma Company |
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
|
US6162804A
(en)
*
|
1997-09-26 |
2000-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6465484B1
(en)
|
1997-09-26 |
2002-10-15 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
WO2000012089A1
(en)
*
|
1998-08-31 |
2000-03-09 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
US6124463A
(en)
*
|
1998-07-02 |
2000-09-26 |
Dupont Pharmaceuticals |
Benzimidazoles as corticotropin release factor antagonists
|
US6365589B1
(en)
|
1998-07-02 |
2002-04-02 |
Bristol-Myers Squibb Pharma Company |
Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
WO2001000656A2
(en)
|
1999-06-29 |
2001-01-04 |
Ortho-Mcneil Pharmaceutical, Inc. |
Novel indazole peptidomimetics as thrombin receptor antagonists
|
US6630451B1
(en)
*
|
1999-06-29 |
2003-10-07 |
Orthomcneil Pharmaceutical, Inc. |
Benzimidazolone peptidometics as thrombin receptor antagonist
|
US6858577B1
(en)
|
1999-06-29 |
2005-02-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Indole peptidomimetics as thrombin receptor antagonists
|
US6365617B1
(en)
|
1999-06-29 |
2002-04-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Indole and indazole urea-peptoids as thrombin receptor antagonists
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
PT1341769E
(en)
|
2000-12-15 |
2007-12-31 |
Vertex Pharma |
Bacterial gyrase inhibitors and uses thereof
|
DE60221804T2
(en)
|
2001-03-12 |
2008-05-15 |
Avanir Pharmaceuticals, San Diego |
BENZIMIDAZOLE DERIVATIVES FOR IGE MODULATION AND CELL PROLIFERATION INHIBITION
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
US7622479B2
(en)
|
2001-11-26 |
2009-11-24 |
Takeda Pharmaceutical Company Limited |
Bicyclic derivative, its production and use
|
TWI276631B
(en)
|
2002-09-12 |
2007-03-21 |
Avanir Pharmaceuticals |
Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
|
AU2003270426A1
(en)
|
2002-09-12 |
2004-04-30 |
Avanir Pharmaceuticals |
PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
|
TW200501960A
(en)
*
|
2002-10-02 |
2005-01-16 |
Bristol Myers Squibb Co |
Synergistic kits and compositions for treating cancer
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
WO2006001266A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
Method for producing 2-arylpurine derivative
|
US7816552B2
(en)
|
2004-09-28 |
2010-10-19 |
Sankyo Company, Limited |
Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same
|
EA012374B1
(en)
*
|
2005-02-08 |
2009-10-30 |
Прозидион Лимитед |
Dihydroimidazothiazole derivatives
|
KR20080013886A
(en)
*
|
2005-04-05 |
2008-02-13 |
파마코페이아, 인코포레이티드 |
Purine and imidazopyridine derivatives for immunosuppression
|
CA2618634A1
(en)
*
|
2005-08-15 |
2007-02-22 |
Irm Llc |
Compounds and compositions as tpo mimetics
|
JP2009523701A
(en)
*
|
2005-12-28 |
2009-06-25 |
武田薬品工業株式会社 |
Fused heterocyclic compounds and uses thereof
|
CN102633783A
(en)
|
2006-02-10 |
2012-08-15 |
转化技术制药公司 |
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
|
KR101504669B1
(en)
|
2006-10-19 |
2015-03-20 |
시그날 파마소티칼 엘엘씨 |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
ES2613664T3
(en)
|
2009-10-26 |
2017-05-25 |
Signal Pharmaceuticals, Llc |
Synthesis and purification procedures of heteroaryl compounds
|
BR112014009755B1
(en)
|
2011-10-19 |
2022-09-13 |
Signal Pharmaceuticals, Llc |
TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
|
CA3125862A1
(en)
|
2011-12-02 |
2013-06-06 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
BR112014020786A2
(en)
|
2012-02-24 |
2020-10-27 |
Signal Pharmaceuticals, Llc |
method for the treatment of lung cancer, method for achieving a response evaluation criterion in solid tumors, method for increasing survival
|
US9550737B2
(en)
*
|
2012-06-11 |
2017-01-24 |
Ucb Biopharma Sprl |
TNF -α modulating benzimidazoles
|
CN103113235A
(en)
*
|
2012-10-15 |
2013-05-22 |
常州大学 |
Method for synthesizing nitryl chloroaniline compound by using micro-channel reactor
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
AU2013365926B9
(en)
|
2012-12-21 |
2019-01-17 |
Zenith Epigenetics Ltd. |
Novel heterocyclic compounds as bromodomain inhibitors
|
CN105188704B
(en)
|
2013-01-16 |
2017-09-19 |
西格诺药品有限公司 |
Substituted Pyrrolopyrimidine compounds, its composition and use its treatment method
|
US9296754B2
(en)
|
2013-03-15 |
2016-03-29 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
US9186361B2
(en)
|
2013-03-15 |
2015-11-17 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
WO2014151630A2
(en)
|
2013-03-15 |
2014-09-25 |
Irm Llc |
Compounds and compositions for the treatment of parasitic diseases
|
JP6382946B2
(en)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
Cancer treatment with dihydropyrazino-pyrazine
|
PE20160041A1
(en)
|
2013-04-17 |
2016-01-28 |
Signal Pharm Llc |
PHARMACEUTICAL FORMULATIONS, PROCESS, SOLID FORMS AND METHODS OF USE RELATED TO 1-ETHYL-7- (2-METHYL-6- (1H-1,2,4-TRIAZOL-3-IL) PYRIDIN-3-IL) -3, 4-DIHYDROPIRAZINO [2,3-b] PIRAZIN-2 (1H) -ONE
|
TW201521725A
(en)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
CA2908957C
(en)
|
2013-04-17 |
2021-05-18 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
TWI631950B
(en)
|
2013-04-17 |
2018-08-11 |
標誌製藥公司 |
Treatment of cancer with dihydropyrazino-pyrazines
|
CA2909625C
(en)
|
2013-04-17 |
2021-06-01 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
JP6401250B2
(en)
|
2013-05-29 |
2018-10-10 |
シグナル ファーマシューティカルズ,エルエルシー |
7- (6- (2-hydroxypropan-2-yl) pyridin-3-yl) -1-((trans) -4-methoxycyclohexyl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 (1H) -one, pharmaceutical composition thereof in solid form, and method of use thereof
|
EP3010917B1
(en)
|
2013-06-21 |
2018-01-31 |
Zenith Epigenetics Ltd. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
CN109939113B
(en)
|
2013-06-21 |
2022-02-15 |
恒翼生物医药科技(上海)有限公司 |
Bicyclic bromodomain inhibitors
|
US9855271B2
(en)
|
2013-07-31 |
2018-01-02 |
Zenith Epigenetics Ltd. |
Quinazolinones as bromodomain inhibitors
|
RS58053B1
(en)
|
2013-12-19 |
2019-02-28 |
Novartis Ag |
[1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
|
CR20160361A
(en)
|
2014-02-11 |
2016-10-03 |
Bayer Pharma AG |
BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
|
WO2015121209A1
(en)
|
2014-02-11 |
2015-08-20 |
Bayer Pharma Aktiengesellschaft |
Benzimidazol-2-amines as midh1 inhibitors
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015160868A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
EA201790189A1
(en)
|
2014-07-14 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
METHODS OF TREATING MALIGNANT NUMER FORMATION USING SUBSTITUTED PYRROPYRYMIDIN COMPOUNDS, COMPOSITIONS ON THEIR BASIS
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
CA2965213A1
(en)
|
2014-10-23 |
2016-04-28 |
Bayer Pharma Aktiengesellschaft |
1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
|
ES2822654T3
(en)
|
2014-10-23 |
2021-05-04 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Benzimidazole-2-amines as mIDH1 inhibitors
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
WO2016087942A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
US10292968B2
(en)
|
2014-12-11 |
2019-05-21 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
US10370339B2
(en)
|
2015-06-08 |
2019-08-06 |
Bayer Pharma Aktiengesellschaft |
N-Methylbenzimidazoles as mIDH1 inhibitors
|
CA2992364A1
(en)
|
2015-07-16 |
2017-01-19 |
Bayer Pharma Aktiengesellschaft |
5-hydroxyalkylbenzimidazoles as midh1 inhibitors
|
MX2021001186A
(en)
|
2015-11-20 |
2022-10-11 |
Forma Therapeutics Inc |
Purinones as ubiquitin-specific protease 1 inhibitors.
|
SG11201912403SA
(en)
|
2017-06-22 |
2020-01-30 |
Celgene Corp |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
Dihydrobenzimidazolones
|
EP3697777A1
(en)
|
2017-10-19 |
2020-08-26 |
eFFECTOR Therapeutics, Inc. |
Benzimidazole-indole inhibitors of mnk1 and mnk2
|
CN113557235A
(en)
|
2019-03-06 |
2021-10-26 |
C4医药公司 |
Heterocyclic compounds for use in medical therapy
|